miR-155 impairs ICOSL and MHC-I expression in DLBCL lymphomas
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2422615122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Esmerina Tili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210. Hauptthemen laut MEDLINE: MicroRNAs, Lymphoma, Large B-Cell, Diffuse, Gene Expression Regulation, Neoplastic, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, R35, CLL Global Research Foundation (CLLGRF).
Abstract (Originalsprache)
Elevated miR-155 levels in B cell malignancies, such as CLL and DLBCL, correlate with increased aggressiveness of the disease. We recently reported that, in two different mouse models of miR-155 -driven B cell malignancy, miR-155 targets and down-regulates transcripts encoding ICOSL, the ligand for the Inducible T cell costimulator (ICOS), thereby impairing the capacity of T lymphocytes to recognize and eliminate malignant cells. In this report, we extend our previous findings to Human by showing that miR-155 levels negatively correlate with those of both ICOSL and MHC-I in samples from DLBCL patients. We present evidence of miR-155 reducing the levels of ICOSL transcripts in ABC, but not in GCB primary tumors (PTs) and cell lines (CLs). In contrast, there was no evidence of miR-155 targeting MHC-I transcript levels in both types of DLBCLs. Nevertheless, miR-155 and MHC-I levels inversely correlated in DLBCLs samples, suggesting the existence of indirect regulatory effects of miR-155 . There was also evidence of dose-dependent effects at low miR-155 levels. Altogether, our findings indicate that the deficiency of both ICOSL and MHC-I activity, driven by high levels of miR-155 , may be causative in the failure of the host immune system to recognize and eliminate malignant B cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210.
- Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
- Gnome, Powell, OH 43065.
ORCID-Profile: Carlo M Croce
Förderung
- NCI NIH HHS
- R35
- CLL Global Research Foundation (CLLGRF)
Zitieren
APA
Tili, E., Commisso, T. L., Balatti, V., Michaille, J. J., Nuovo, G. J., & Croce, C. M. (2025). miR-155 impairs ICOSL and MHC-I expression in DLBCL lymphomas. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2422615122
Vancouver
Tili E, Commisso TL, Balatti V, Michaille JJ, Nuovo GJ, Croce CM. miR-155 impairs ICOSL and MHC-I expression in DLBCL lymphomas. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2422615122
BibTeX
@article{Tili2025,
author = {Tili, Esmerina and Commisso, Teresa L and Balatti, Veronica and Michaille, Jean-Jacques and Nuovo, Gerard J and Croce, Carlo M},
title = {miR-155 impairs ICOSL and MHC-I expression in DLBCL lymphomas},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2422615122}
}
EUVIMED